| scholarly article | Q13442814 |
| P2093 | author name string | Allison W Kurian | |
| Shaveta Vinayak | |||
| P2860 | cites work | Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. | Q52994367 |
| The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. | Q53368104 | ||
| Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. | Q53407386 | ||
| Caveolin-1 inhibits breast cancer growth and metastasis | Q57369965 | ||
| Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study | Q58217064 | ||
| The Risk of Cancer in Users of Statins | Q63865877 | ||
| Statin use and the risk of breast cancer | Q73341602 | ||
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study | Q74116896 | ||
| Differential modulation of caveolin-1 expression in cells of the vasculature by statins | Q75302836 | ||
| Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis | Q77513498 | ||
| Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways | Q80726286 | ||
| Chemoprevention of breast cancer | Q80955303 | ||
| Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase | Q24645348 | ||
| Osteoblast-derived Oxysterol Is a Migration-inducing Factor for Human Breast Cancer Cells | Q28195859 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals | Q33688733 | ||
| Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). | Q34164324 | ||
| Statins and cancer risk: a meta-analysis | Q34481478 | ||
| Statins and risk of cancer: a systematic review and metaanalysis | Q34585294 | ||
| The statins as anticancer agents | Q35049816 | ||
| Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update | Q36014966 | ||
| Statin use and breast cancer risk in a large population-based setting | Q36120856 | ||
| Breast-tissue sampling for risk assessment and prevention | Q36157643 | ||
| Statin use and breast cancer: prospective results from the Women's Health Initiative. | Q36480676 | ||
| Statin use and cancer risk in the General Practice Research Database | Q36694570 | ||
| Translational approaches for the prevention of estrogen receptor-negative breast cancer | Q36784148 | ||
| Statins and cancer: A systematic review and meta-analysis | Q37245345 | ||
| Statins and breast cancer: may matrix metalloproteinase be the missing link | Q37393969 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. | Q40204582 | ||
| Breast cancer growth prevention by statins | Q40236401 | ||
| Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion | Q40517903 | ||
| Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study | Q40790232 | ||
| Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect | Q40808465 | ||
| Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. | Q40809878 | ||
| Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. | Q40995647 | ||
| Cholesterol inhibition, cancer, and chemotherapy | Q41089488 | ||
| Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis | Q42816384 | ||
| Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. | Q44052545 | ||
| Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users | Q44252782 | ||
| Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. | Q44265649 | ||
| Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells | Q44507023 | ||
| Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). | Q45036700 | ||
| Serum lipids, lipid-lowering drugs, and the risk of breast cancer | Q46772398 | ||
| Statin use and risk of breast cancer | Q46896215 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 148-156 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Current breast cancer reports | Q26842500 |
| P1476 | title | Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease | |
| P478 | volume | 1 |
| Q38522989 | Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes |
| Q34185642 | Lipophilic statin use and risk of breast cancer subtypes |
| Q38712771 | Racial differences in the effects of comorbidity on breast cancer-specific survival |
| Q57790350 | Statin use and risk of contralateral breast cancer: a nationwide cohort study |
| Q37137519 | The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women |
Search more.